Product Information

DOLOBID 250 MG TABLET is a generic product labeled by INA Pharmaceutics Inc, priced at $20.4233 per EA under NDC 74157000960. Its NADAC has been published 10 times since Sep 17, 2025.

FDA first approved this application on Mar 8, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the Diflunisal market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

DOLOBID 250 MG TABLET

Diflunisal
$20.4233per EA
High Outlier

Strength

250 mg/1

NDC

74157000960

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

DIFLUNISAL

Approval Type

Generic (ANDA)

FDA Application

ANDA202845

FDA Approved

3/8/2012

TE Code

AB

On Market Since

8/19/2024

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug

Price Statistics

The NADAC for DOLOBID 250 MG TABLET has been published 10 times since Sep 17, 2025, and over the history we have for it it has declined 10.7%. The table below summarizes its recorded NADAC range and movement.

Current price$20.4233 per EA
All-time high$22.8653 (Oct 15, 2025)
All-time low$20.4233 (Nov 18, 2026)
52-week high$20.6317
52-week low$20.4233
Median price$21.7485
Average price$21.7276
Largest weekly change-9.8% (Oct 21, 2026)
Weeks tracked10
Tracking sinceSep 17, 2025

Price History

1W

-1.0%

1M

-10.7%

3M

-10.7%

6M

-10.7%

1Y

-10.7%

3Y

N/A

5Y

N/A

All

-10.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Diflunisal market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DOLOBID 250 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for DOLOBID 250 MG TABLET, manufactured by INA Pharmaceutics Inc, is $20.4233 per EA (NDC 74157000960), effective Nov 18, 2026.

How has the price of DOLOBID 250 MG TABLET changed over time?

Over the history we have for it, the NADAC for DOLOBID 250 MG TABLET has declined 10.7%. It has been tracked across 10 weekly CMS publications since Sep 17, 2025.

What are the highest and lowest recorded NADAC prices for DOLOBID 250 MG TABLET?

Since Sep 17, 2025, the NADAC for DOLOBID 250 MG TABLET has ranged from a low of $20.4233 (Nov 18, 2026) to a high of $22.8653 (Oct 15, 2025), with a median of $21.7485 per EA.

Are there cheaper alternatives to DOLOBID 250 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of DOLOBID 250 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DOLOBID 250 MG TABLET?

DOLOBID 250 MG TABLET (NDC 74157000960) is labeled by INA Pharmaceutics Inc, and CMS classifies it as a generic product.